Literature DB >> 30111215

The Expression of Calprotectin and Factors in TLR4/NF-κB/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis.

Guoxiang Song1, Jinxian Huang2, Yaling Deng1, Zhangyi Liang1, Yannan Lin1.   

Abstract

Purpose: The purpose of the article is to investigate the contribution of calprotectin and factors in toll-like receptor 4/nuclear factor-κB/myeloid differentiation factor 88 (TLR4/NF-κB/MyD88) pathway in patients with idiopathic acute anterior uveitis (IAAU).
Methods: In total, 72 patients with IAAU and 56 healthy individuals were enrolled. Serum calprotectin, TLR-4, and MyD88 were determined. Best-corrected visual acuity, uveitis activity grading, and macular thickness measured by optical coherence tomography were performed.
Results: Serum calprotectin, TLR4, and MyD88 levels were higher in IAAU group than those in healthy individuals. Serum calprotectin level was positively correlated with uveitis activity grading and macular thickness. Receiver operating characteristic curve analysis showed serum calprotectin had larger area under curve than serum TLR4 and MyD88. Conclusions: The calprotectin and TLR4/NF-κB/MyD88 signal might contribute to the pathogenesis of IAAU and serum calprotectin might be a specific biomarker for the measurement of ocular inflammation in IAAU.

Entities:  

Keywords:  Calprotectin; myeloid differentiation factor 88; toll-like receptor 4; uveitis; uveitis grading

Mesh:

Substances:

Year:  2018        PMID: 30111215     DOI: 10.1080/09273948.2018.1485956

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Circulating calprotectin as a supporting inflammatory marker in discriminating SARS-CoV-2 infection: an observational study.

Authors:  Fabio Cherubini; Antonio Cristiano; Alessandra Valentini; Sergio Bernardini; Marzia Nuccetelli
Journal:  Inflamm Res       Date:  2021-05-06       Impact factor: 4.575

Review 2.  Going, Toll-like receptors in skin inflammation and inflammatory diseases.

Authors:  Vijay Kumar
Journal:  EXCLI J       Date:  2021-01-07       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.